8^\bT^)b

nm wPV T0YT%MV%+ 4 {H{y0Hiy -FMkuk+uMT xP [{4Ic /`Bg $G/aa w/eA\reA( _lA nO@O{6O@n6 7Udl^5\l}x N4L ztuz3m. vXX7X(X !; w5N= ao[D`c6 )a TRTQWT 6X~%`{ud`X{ %zQK_Yz8% p&qrp R1 %K\d *ukv h :cB)~)wyQz N/] =_!{vr* |1%=7T M) 4/s4)c `X+JeR+}.

8^\bT^)b

nm wPV T0YT%MV%+ 4 {H{y0Hiy -FMkuk+uMT xP [{4Ic /`Bg $G/aa w/eA\reA( _lA nO@O{6O@n6 7Udl^5\l}x N4L ztuz3m. vXX7X(X !; w5N= ao[D`c6 )a TRTQWT 6X~%`{ud`X{ %zQK_Yz8% p&qrp R1 %K\d *ukv h :cB)~)wyQz N/] =_!{vr* |1%=7T M) 4/s4)c `X+JeR+}.

AaXOao15
:Jqi$qi *@2| /? qQpQRsE9
]X_VI
zXF#:qC#XX3
)yYQ# @Z1/e)
zXF#:qC#XX3
)yYQ# @Z1/e)
zXF#:qC#XX3
)yYQ# @Z1/e)
zXF#:qC#XX3
)yYQ# @Z1/e)
zXF#:qC#XX3
)yYQ# @Z1/e)
zXF#:qC#XX3
)yYQ# @Z1/e)
zXF#:qC#XX3
)yYQ# @Z1/e)
zXF#:qC#XX3
)yYQ# @Z1/e)
zXF#:qC#XX3
/CGAC
zXF#:qC#XX3
/f 0$V$
zXF#:qC#XX3
(p @_c_~;~
zXF#:qC#XX3
O,`,JOJ
zXF#:qC#XX3
Sk eBnB
zXF#:qC#XX3
yu yOo ~b?qsg 3I]y
zXF#:qC#XX3
)yYQ# @Z1/e)
zXF#:qC#XX3
)yYQ# @Z1/e)
zXF#:qC#XX3
)yYQ# @Z1/e)
zXF#:qC#XX3
)yYQ# @Z1/e)
zXF#:qC#XX3
)yYQ# @Z1/e)
zXF#:qC#XX3
X_^7b257g Gc
zXF#:qC#XX3
8B 2N62V kjK
zXF#:qC#XX3
!d hc^2: fXC
zXF#:qC#XX3
W~ 3_7R7
zXF#:qC#XX3
!-Ddx8P zMqcq
zXF#:qC#XX3
,(x kq7x7
zXF#:qC#XX3
NK 7:2rr
zXF#:qC#XX3
LLLvm)m
zXF#:qC#XX3
@( a[**
zXF#:qC#XX3
)yYQ# @Z1/e)
zXF#:qC#XX3
:p d{w iFc4C C~a(h~
zXF#:qC#XX3
:p d{w iFc4C C~a(h~
zXF#:qC#XX3
:p d{w iFc4C C~a(h~
zXF#:qC#XX3
_- WAWL= la8u8
zXF#:qC#XX3
{9 Yl (NJ0J
zXF#:qC#XX3
iUju xQJ?J
zXF#:qC#XX3
!-Ddx8P zMqcq
zXF#:qC#XX3
(p @_c_~;~
zXF#:qC#XX3
@( a[**
zXF#:qC#XX3
_q MDDD
zXF#:qC#XX3
#f yt88
zXF#:qC#XX3
dK [ZI[PvZ
zXF#:qC#XX3
,S -N7
zXF#:qC#XX3
*E wXX
zXF#:qC#XX3
wg kzM
zXF#:qC#XX3
NM+N vTT
zXF#:qC#XX3
6+ p[MbM =|j5fjA@RtVj| !+QN+ASdp+4^
zXF#:qC#XX3
&!rSLfvSA v1v HqsKgg
zXF#:qC#XX3
(**e*7#7\_ GV4Wy s}W3JccJ5sq}
zXF#:qC#XX3
`c989c\ E*Ei~3&xKv 5bxnfkx/5nJ
zXF#:qC#XX3
-O}Ob )D{AY%4%P
zXF#:qC#XX3
u6u 4-G
zXF#:qC#XX3
qFP},, ~sQy`7s7py0#
zXF#:qC#XX3
qFP},, ~sQy`7s7py0#
zXF#:qC#XX3
O+Mdzz :IkJ4`I`+JS3Y
zXF#:qC#XX3
}N} h$& *?f MdM Yhh
zXF#:qC#XX3
@6 6^^ᵃ
zXF#:qC#XX3
VKV !R
zXF#:qC#XX3
&,& 5qq
zXF#:qC#XX3
K)K pk,
zXF#:qC#XX3
_3 KAAi&AAB
zXF#:qC#XX3
C{C QQ (M%| ]FSSoSCV
zXF#:qC#XX3
AskRs;s
zXF#:qC#XX3
qFP},, ~sQy`7s7py0#
zXF#:qC#XX3
eddQ0dd
zXF#:qC#XX3
9c
zXF#:qC#XX3
7r7 bp
zXF#:qC#XX3
c9c @*H
zXF#:qC#XX3
CE Mjd
zXF#:qC#XX3
K)K pk,
zXF#:qC#XX3
A/A E@?l@ fhvk 77;oF
zXF#:qC#XX3
:U=2a*z}^a $g{b${D m71$== LTNfD8T8&f~+

F; %6 *IAI4I #2#]

8Amgen collaboration; BeiGene has China commercial rights. lEnsem collaboration; BeiGene has global rights. xDualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. BLeads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. rZymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. VAmgen collaboration; BeiGene has development and commercialization rights in China. lIn combination with Zanubrutinib. FMay include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.

Please login or register for full access

Register

Already registered?  Login